The links in the table below take you to informal pages on this site which list summaries of and comments on the current clinical trials for ALL. Many parents combined resources to gather this information, many thanks to all of them! If you have information or comments to add, feel free to email the editor as linked at the bottom of each page.
The links to the clinical trials on the cancer.gov site sometimes change as the cancer.gov site re-organizes. As of 4/06, you go to the main (advanced) search page on cancer.gov and select the type of cancer, then select whether the trial is open or closed and the Protocol ID. You can also search for all available trials by entering in other applicable information and leaving the Protocol ID field empty.
Relapse Protocols: On another page/site
|trial||dates||risk||aim of trial is to compare:|
|CCG 1901||around 1994||high||New York I and II|
|CCG 1922||early 1990s
|favorable to intermediate||IV vs oral 6-MP
dexamethasone vs prednisone
|standard risk||TG vs MP
TIT vs methotrexate IT
|CCG 1961|| 1996-2000
|high risk|| one vs two delints
standard vs intensified chemo
|CCG 1991||2001 (closed to accrual)||standard risk||Escalating dose IV MT (w/o leucovorin rescue) vs oral MT
single vs double delints
|POG 9904||2001 (closed to accrual)||low-risk||Compare short methotrexate infusion vs longer infusion.
Compare the above regimens of methotrexate, with or without intensification.
Less-intensive treatment for trisomy 4, 10; checking if can do the same for tel/aml t(12;21)
|POG 9905||2001 (closed to accrual)||standard risk||Determine if delayed intensification improves outcome.
Compare short methotrexate infusion (4 hours) vs longer infusion (24 hours).
Determine the correlation between EFS, MRD, and RER in standard risk patients.
|POG 9906||2001 (closed to accrual)||high risk||Determine whether augmented BFM therapy is superior to ALinc 14/15 therapy.|
|St Judes total therapy XV
(email the editor if interested in details)
|2000||all risk groups||St Judes site|
|T-cell||Modified BFM with or without Nelarabine (Ara G pro-drug) in T-cell patients.|
|DFCI 00-01||(current in 2003)||T-cell|
|POG 9404||(closed to accrual but still used)||The main purpose of this study is to determine whether adding high dose methotrexate to other chemotherapy drugs is more effective in treating T-ALL and T-NHL.|
|POG 9406||closed||high risk||standard vs high dose methotrexate
standard araC/teniposide vs high dose ara C/asparaginase rescue
|moderate risk||to determine if delayed intensification with divided dose oral MTX improves efs
compare effect of twice vs once daily MP
activated about 4/2005
closed late 2010
|standard risk (further classified as low-, average-, and high-risk)
ages 0-9, WBC less than 50K at dx, pre-B
|COG-AALL0232||closed early 2011
pre-B and age greater than 9 or WBC greater than 50K at dx
|dexamethasone vs prednisone during induction
escalating dose methotrexate vs high dose methotrexate with leucovorin rescue during interim maintenance
|activated 2008||infant ALL||Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib)|
|COG-AALL0434||activated 2007||T-cell ALL||intensified mtx, Nelarabine, augmented BFM|
|activated 2010||NCI standard risk ALL and average risk ALL as determined by therapy response and/or genetics||studies different maintenance therapy strategies for average risk patients (different 6MP doses and vincristine/dexamethasone pulses at 4 vs 12 week periods); standard risk patients have follow one of two different consolidation strategies; Downs syndrome patients have a separate arm|
|activated 4/2012||high-risk ALL||Phase III Randomized Study of Consolidation Therapy, Interim Maintenance Therapy, Delayed Maintenance Therapy, and Maintenance Therapy in Children, Adolescents, and Young Adults With Newly Diagnosed High-Risk B-precursor Acute Lymphoblastic Leukemia|
|activated 2011||phase II trial for Ph+ ALL||Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia - Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL).|
|activated 2011, closed to accrual 2012||NCI phase III trial for Ph+ ALL||intensified Dasatinib therapy|
|POG 9201||92-96?||low risk||?|
|CCG 1901||(early 90s)||high risk|
|RCCHOS||high risk||NOTE: this trial is used in S. Africa|
|Toronto Protocol C||high risk|
Would you like to add information? Email Patty.
Ped-Onc Resource Center Home
General Disclaimer : These pages are intended for informational purposes only and are not intended to render medical advice. The information provided on Ped Onc Resource Center should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you suspect your child has a health problem, you should consult your health care provider.
Last Updated 2/08
© copyright 1998-2018 by Patty Feist
email the editor